13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001608126
Total reported value
$2.8B
$2.8B
26 檔
49.1%
According to the latest 13F quarterly dataset, Finepoint Capital LP managed an equity portfolio of $2.8B at the end of Q4 2024, spanning 26 distinct U.S. exchange-listed positions.
During Q4 2024, Finepoint Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 27.02% | +10.54% | +36.04% | |
| 2 | QXO | Qxo Inc | Stock-Industrials | 24.21% | -2.60% | -3.17% | |
| 3 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 20.04% | — | +39.44% | |
| 4 | LBRDK | Liberty Broadband-c | Stock-Comm Services | 9.20% | — | +1.06% | |
| 5 | LLYVK* | Liberty Media Corp-liberty-c | Stock-Other | 3.38% | — | — | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.99% | — | -2.76% | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.90% | — | -2.96% | |
| 8 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.65% | — | +15.04% | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 1.55% | — | -2.74% | |
| 10 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.48% | — | +15.20% | |
| 11 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.20% | — | +21.27% | |
| 12 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 1.13% | — | +20.98% | |
| 13 | XNCR | Xencor Inc | Stock-Other | 0.93% | — | — | |
| 14 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.91% | — | +24.18% | |
| 15 | ARVN | Arvinas Inc | Stock-Other | 0.84% | — | +24.27% | |
| 16 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.69% | — | — | |
| 17 | PRTA | Prothena Corporation plc | Stock-Other | 0.56% | — | +51.58% | |
| 18 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.55% | — | +33.79% | |
| 19 | EYPT | Eyepoint Inc | Stock-Other | 0.51% | — | +57.07% | |
| 20 | SLDB | Solid Biosciences Inc | Stock-Other | 0.23% | — | — | |
| 21 | ANNA | Aleanna Inc | Stock-Other | 0.01% | -0.01% | — | |
| 22 | ANNAW | Aleanna Inc - Cl A - 29 | Stock-Other | — | -0.01% | — | |
| 23 | ✓ | Moneyhero Limited | Stock-Other | — | — | — | |
| 24 | ✓ | Summit Healthcare Acquisition | Stock-Other | — | — | — | |
| 25 | ✓ | Marblegate Acquisition CORP | Stock-Other | — | — | — | |
| 26 | ✓ | Calidi Biotherapeutics Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Finepoint Capital LP reported a total U.S. public equity portfolio value of $2.8B across 26 disclosed positions in Q4 2024.
During Q4 2024, Finepoint Capital LP's top holdings by market value included SPY (27.0%)、QXO (24.2%)、IWM (20.0%). The largest single position, SPY, represented 27.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, QXO, IWM) accounted for 49.1% of total reported equity market value during Q4 2024.
In Q4 2024, Finepoint Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.